Ark Biopharma Gets China Approval for Aizhida to Treat ADHD
Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced that China’s National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and...